New Non-Hormonal Treatment for Menopause Symptoms Recommended by NICE
The National Institute for Health and Care Excellence has recommended fezolinetant as a new non-hormonal treatment option for moderate to...
Filter:
CQC Highlights Good Practice in Dementia Care
Dementia care isn’t just about treatment, it’s about experience. New research from the Care Quality Commission highlights what high-quality dementia...
Seamless EMIS, SystmOne & Docman Integration | Ashtons Virtual Hub
Integrating new services into existing clinical systems can be a major headache for GP practices and PCNs. That’s why we’ve...
Anaphylaxis Nasal Spray Treatment Approved by MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the UK’s first needle-free treatment for anaphylaxis. The adrenaline nasal...
LHON Eye Disease Treatment Recommended by NICE
Hundreds of people in England living with inherited vision loss could benefit from a newly recommended eye disease treatment. NICE...
First NHS 24/7 Mental Health Unit Opens
The first of its kind, this walk-in crisis hub will provide round-the-clock care for patients in urgent need of mental...
NHS Expands Access to Cystic Fibrosis Triple Therapy
NHS announces major expansion of cystic fibrosis treatment access. Hundreds more children and adults will now be eligible for life-changing...
NICE Recommends Nemolizumab for Moderate to Severe Atopic Dermatitis
NICE has issued final guidance recommending nemolizumab (Nemluvio) as a treatment option for people aged 12 and above with moderate...
How the NHS’s 10 Year Plan aligns with Ashtons
The NHS has set out a bold vision for the future. It aims to shift care out of hospitals, embrace...
MHRA Approves UK’s First Anti-PD-1 Monoclonal Antibody for Aggressive Lung Cancer
The MHRA has authorised the UK’s first anti-PD-1 monoclonal antibody, serplulimab, for adults with treatment-naïve extensive-stage small-cell lung cancer. The...
NHS First in the World to Roll Out “Trojan Horse” Drug for Blood Cancer
NHS England has announced the national rollout of belantamab mafodotin, a first-in-class “Trojan horse” therapy for patients with relapsed or...
Artificial Pancreas Systems Transforming Lives of Children and Young People with Type 1 Diabetes
NICE has confirmed that approximately 20,000 children and young people in England are now using hybrid closed loop (HCL) systems—so-called...